Because the low/absent expression of INVS and the high expression of DVL3 were recorded in tumors that developed metastases, they could be used as additional diagnostic tools in early ccRCC to form an individualized follow-up of the patients and to predict a possible relapse in patients who are at a greater risk, or to involve those uncostly criteria as possible additions, including the risk factors for the treatment with adjuvant immunotherapy. This evidence concerns the gene DVL3 and nonpapillary renal cell carcinoma.